Inventiva, a clinical-stage biopharmaceutical company, has temporarily halted trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 a.m. CEST. This pause is at the company's request and precedes a proposed financing transaction, with details to be announced later. Trading is expected to resume the same day around 3:30 p.m. CEST, coinciding with the start of trading on Nasdaq under the ticker IVA. This move is significant as it prepares the market for upcoming financial developments related to Inventiva's clinical programs for metabolic liver disease treatments.
Fulcrum Therapeutics' stock dropped nearly 50% in after-hours trading after the company announced it is discontinuing its lead experimental drug, pociredir, for sickle cell disease. The decision follows FDA concerns about cancer risks linked to the d...
Inventiva, a clinical-stage biopharmaceutical company, has temporarily suspended trading of its ordinary shares on Euronext Paris starting June 2, 2026, at 9:00 CEST. This suspension is at the company's request and precedes a planned financing operat...
The FDA has accepted Roche's New Drug Application for giredestrant, an oral selective estrogen receptor degrader (SERD), as an adjuvant treatment for early-stage ER-positive, HER2-negative breast cancer. The approval decision is expected by November ...
dsm-firmenich announced ongoing progress in its share repurchase program, buying back 184,000 shares between May 25-29, 2026, at an average price of €72.36 per share, totaling €13.3 million. This is part of a larger €540 million buyback initiated in ...
Sika has appointed Philipp Irniger as the new Head of Construction and member of Group Management, succeeding Ivo Schädler who will retire in March 2027. Irniger brings extensive international experience and will lead Sika's global construction busin...
